Mednet Logo
HomePulmonology
Pulmonology

Pulmonology

Physician discussions on respiratory conditions, critical care, interstitial lung disease, and pulmonary procedures.

Recent Discussions

Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?

5
2 Answers

Mednet Member
Mednet Member
Nephrology · Ohio State Department Of Nephrology

The duration of maintenance therapy in patients with AAV depends on many factors and should be individualized. Some factors that are associated with a higher risk of relapse include PR3 positivity, seroconversion from negative to positive, ENT disease, use of a tailored approach to RTX dosing, and u...

How do you risk stratify patients with different WHO groups of pulmonary hypertension prior to non-cardiac surgeries?

2
1 Answers

Mednet Member
Mednet Member
Pulmonology · Hospital of the University of Pennsylvania

First, I would direct the audience to recent AHA guidelines on the perioperative management of PH in non-cardiac surgery. Rajagopal et al., PMID 36924225In general, the severity of pulmonary hypertension and relevant comorbidities are likely more important than the WHO group. In patients with CTEPH,...

What is your approach to de-escalation of asthma therapy if patients have remained clinically stable on triple inhaler therapy and a biologic agent?

1
1 Answers

Mednet Member
Mednet Member
Pulmonology · Augusta University Medical College Of Georgia

Since the reason most folks need biologics is prednisone and considering the side effects, getting patients down to the lowest dose is beneficial.

How do you treat CTD-associated organizing pneumonia?

2 Answers

Mednet Member
Mednet Member
Rheumatology · Northwestern Medical Group

The approach to CTD-associated organizing pneumonia is similar to that of CTD-associated NSIP and involves treatment with glucocorticoids and steroid-sparing agents. The evidence for the choice of steroid-sparing agents is extrapolated from clinical trial and observational data from systemic scleros...

Do you use any drugs prophylactically to reduce the risk of radiation pneumonitis in lung SBRT?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Tennessee Oncology

I have not although there are varying levels of evidence to support each of these agents. I think it points to a broader failure as a field to develop radioprotective strategies that could enhance our therapeutic ratio. RTOG 0123 made an attempt at a prospective evaluation of captopril to reduce rad...

When do you screen for pulmonary hypertension in ILD patients?

1 Answers

Mednet Member
Mednet Member
Pulmonology · Cleveland Clinic

Pulmonary hypertension (PH) is a frequent finding in patients with advanced interstitial lung disease (ILD) and its presence is associated with worse morbidity and mortality. The prevalence of PH will depend on the severity of ILD, ranging from around 10% at diagnosis and about 60% of patients with ...

Is the adage “If GCS <8, intubate” still relevant for non-TBI patients?

2 Answers

Mednet Member
Mednet Member
Pulmonology · Augusta University Medical College Of Georgia

It's a challenging area. NICO does lead credence to withholding intubation among patients that are comatose from acute poisoning with improvements in "composite end point of in-hospital death, length of ICU stay, and length of hospital stay."Practically speaking, I've never liked hard and fast rules...

When would you consider biopsy for an incidentally noted, PET negative, solid, solitary pulmonary nodule that is >8mm in size?

1 Answers

Mednet Member
Mednet Member
Pulmonology · Rogel Cancer Center/University of Michigan

No, probably not. The whole point of a PET scan is to use it for its negative predictive value (which is very high for a nodule that is solid, and large enough). I'd like to know just how large it is because smaller nodules (e.g. just at or above the 8 mm size threshold we all perseverate on) can be...

What steroid regimen do you use in patients with both septic shock and ARDS?

1
2 Answers

Mednet Member
Mednet Member
Pulmonology · Duke University Medical Center

Personally, I have used Hydrocortisone 50mg q6h for patients with refractory shock, regardless of the presence of absence of ARDS. I have not been an adopter of Steroids in ARDS.

What is your approach to treatment for MDA5 dermatomyositis patients with rapidly progressive ILD?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · The University of Texas Health Science Center at Houston (UTHealth)

Rapidly progressive ILD is a temporal term, describing rapidly declining lung function within weeks (usually defined as 3 months). Therefore, we commonly use this term when the patient is already hospitalized with respiratory failure. The majority of the data stem from Japan and China, where they en...